| Identification | Back Directory | [Name]
ABT 107) | [CAS]
855291-54-2 | [Synonyms]
ABT 107)
ABT-107
(ABT107
(R)-3-((6-(1H-Indol-5-yl)pyridazin-3-yl)oxy)quinuclidine
1-Azabicyclo[2.2.2]octane, 3-[[6-(1H-indol-5-yl)-3-pyridazinyl]oxy]-, (3R)- | [Molecular Formula]
C19H20N4O | [MOL File]
855291-54-2.mol | [Molecular Weight]
320.39 |
| Chemical Properties | Back Directory | [Boiling point ]
598.0±50.0 °C(Predicted) | [density ]
1.33±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
16.01±0.30(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions[1][2]. | [in vivo]
ABT-107 exhibits good bioavailability in mouse (orally, 51.1%; intraperitoneally,100%), rat (orally, 81.2%; intraperitoneally, 100.0%), and monkey (orally, 40.6%; intramuscularly,
100%), and good CNS penetration in rodents with a brain/plasma ratio of 1[1].
ABT-107 (0.01-1 μmol/kg i.p., 15 min before sacrifice) produces a dose-dependent increase in ERK1/2 and CREB[1].
ABT-107 (0.01, 0.1, and 1.0 mg/kg i.p.) increases S9-GSK3 and decreases p-tau in mouse cortex and hippocampus in mice[1].
ABT-107 (5 mg/kg/day i.p.) infusion attenuates tau hyperphosphorylation in AD transgenic APP-tau mice[1].
| Animal Model: | Rats (male Sprague-Dawley; 350-380 g b.wt.)[1]. | | Dosage: | 1, 3 μmol/kg. | | Administration: | I.P. daily for 3 consecutive days. | | Result: | Induced a significant, dose-dependent increase in ACh release by day 3 of repeated administration.
Higher doses may be required to evoke ACh release in naive rats not engaged in stimulated, i.e., cognitive-related behavior.
|
| Animal Model: | Female TAPP (and wild-type littermates) mice[1]. | | Dosage: | 1 mg/kg. | | Administration: | Continuous subcutaneous infusion for 2 weeks. | | Result: | Produced a dose-dependent increase in Ser9 phosphorylation in the cingulate cortex 15 min after acute administration in mice. |
| [References]
[1] R Scott Bitner, et al. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86. DOI:10.1124/jpet.110.167213
[2] Tanuja Bordia, et al. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Exp Neurol. 2015 Jan;263:277-84. DOI:10.1016/j.expneurol.2014.09.015 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|